Press Release

Eckert & Ziegler Abstract Award for Young Scientists Specializing in the Area of Nuclear Medicine Enters its 6th Round

Berlin, 8 March 2013. Eckert & Ziegler is presenting its Abstract Award for the sixth time in a row. Up to 8 April 2013, young scientists can once again participate in the competition with their innovative scientific research in the field of nuclear medicine. The travel grant, which is awarded every year, has been established to support young scientists and doctoral students who would like to present the results of their scientific research to a wide audience – at the Annual Congress of the European Association of Nuclear Medicine (EANM) in October 2013. Five travel grants, in the amount of 1,000 EUR each, will be awarded by Eckert & Ziegler AG (ISIN DE0005659700), one of the leading European manufacturers of isotope products and the European Association of Nuclear Medicine (EANM). The award winners will be selected in cooperation with the EANM. The five winners will receive their awards on 23 October 2013 during the EANM Congress in Lyon.
 
The goal of the Eckert & Ziegler/EANM abstract award is to strengthen the collaboration between researchers and clinicians to expedite the implementation of research findings for the benefit of the patient. We hope that this will help to ensure that the substantial progress which has been made in medical imaging can soon be transformed into more precise, faster or less expensive methods of diagnosis and therapy.

“In nuclear medicine, a large number of radiopharmaceuticals are based on what is a partially uncertain situation concerning raw materials. This has been made clear to us very recently by the shortage of raw materials for the widely used Technetium generators. So it is good to know there are alternatives. For example, the raw material for Gallium generators is produced in cyclotrons rather than in high-maintenance nuclear reactors. Nor is there any uncertainty at all in the supply of the Yttrium-90 nuclide, which is used for therapeutic purposes, while Lutetium-177 once again comes from nuclear reactors. With a view towards even greater reliability in terms of treatment, I would like to see more applied research being invested in alternative non-reactor nuclides”, explained Dr. André Heß, Member of the Executive Board at Eckert & Ziegler AG and Head of the Radiopharma business segment.

Eckert & Ziegler

The Eckert & Ziegler Group, with more than 600 employees, is one of the world’s largest providers of isotope component technology for radiation therapy and nuclear medicine. Eckert & Ziegler supports the wide-spread use of PET/CT hybrid systems by expanding its production sites for radioactive contrast agents and by developing automated synthesis modules in which scientists can produce new diagnostic substances with the requisite pharmaceutical quality.

Eligibility for Participation

All EANM members who are not older than 38 years of age at the time of submission are eligible to participate. Applications can be submitted electronically via eanm13.eanm.org. The submission deadline is 8 April 2013.

For further information, please contact:
Eckert & Ziegler AG, Karolin Riehle, Public Relations Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 941084-138, Fax -112
Email: karolin.riehle@dont-want-spam.ezag.de, www.ezag.de